Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X about a paper by Uwe Platzbecker et al. published in Journal of Clinical Oncology:
“APOLLO phase III trial: Compared ATRA + ATO + low-dose idarubicin vs standard ATRA + chemotherapy in newly diagnosed high-risk APL.
Results: 2-year event-free survival 88% vs 71% (HR 0.4, P = .02); molecular relapse 1.5% vs 12.3%; serious adverse events 32% vs 68%.
Conclusion: ATO-based regimen achieved superior efficacy and lower toxicity, supporting it as a new standard for high-risk APL.“
Title: Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial
Authors: Uwe Platzbecker, Lionel Adès, Pau Montesinos, Emanuele Ammatuna, Pierre Fenaux, Claudia Baldus, Massimo Bernardi, Céline Berthon, Monica Bocchia, Caroline Bonmati, Erika Borlenghi, Martin Bornhäuser, Diana Carp, Sylvain Chantepie, Enrico Crea, Mariadomenica Divona, Hartmut Döhner, Gerhard Ehninger, Jordi Esteve Reyner, Jamilé Frayfer, Ana Garrido Diaz, Cristina Gil, Luca Guarnera, Anna Franziska Hamm, Maël Heiblig, Daniela Heidenreich, Alwin Johannes Krämer, Marie-Pierre Ledoux, Monia Lunghi, Valentina Mancini, Klaus Metzeler, Maria Cristina Miggiano, Carsten Müller-Tidow, Pierre Peterlin, Alfonso Piciocchi, Kathrin Rieger, Christoph Röllig, Giovanni Rossi, Miguel A. Sanz, Hubert Serve, Maaike Söhne, Karsten Spiekermann, Emmanuelle Tavernier-Tardy, Christian Thiede, Susana Vives Polo, Wichard Vogel, Patrizia Zappasodi, Pauline Ziller-Walter, and Maria Teresa Voso.
More posts featuring Talha Badar.